Combination of imipenem and TAK-242, a Toll-like receptor 4 signal transduction inhibitor, improves survival in a murine model of polymicrobial sepsis

Shock

Volumn 35, Issue 2, 2011, Pages 205-209

  Sha, Takukyu ^a   Iizawa, Yuji ^b   Ii, Masayuki ^c  

^a Pharmacological Research Laboratory   (Japan)

^b Global Research Management Department   (Japan)

^c TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

abdominal infection; Cecal ligation and puncture; mortality; TAK 242; TLR4 inhibitor

Indexed keywords

ALANINE AMINOTRANSFERASE; IMIPENEM; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 2; NITROGEN; RESATORVID; UREA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL COUNT; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG EFFICACY; FEMALE; LIGATION; MOUSE; MULTIPLE ORGAN FAILURE; NONHUMAN; POLYMICROBIAL SEPSIS; PROTEIN BLOOD LEVEL; PUNCTURE; SEPSIS; SURVIVAL RATE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; UREA NITROGEN BLOOD LEVEL;

EID: 85027943411     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/SHK.0b013e3181f48942     Document Type: Article

References (26)

1. Tsujimoto H, Ono S, Efron PA, Scumpia PO, Moldawer LL, Mochizuki H: Role of Toll-like receptors in the development of sepsis. Shock 29:315-321, 2008.
2. Tsan MF, Gao B: Endogenous ligands of Toll-like receptors. J Leukoc Biol 76:514-519, 2004.
3. Cohen J: The immunopathogenesis of sepsis. Nature 420:885-891, 2002.
4. Andonegui G, Kerfoot SM, McNagny K, Ebbert KV, Patel KD, Kubes P: Platelets express functional Toll-like receptor-4. Blood 106:2417-2423, 2005.
5. Opal SM: The host response to endotoxin, antilipopolysaccharide strategies, and the management of severe sepsis. Int J Med Microbiol 297:365-377, 2007.
6. Ii M, Matsunaga N, Hazeki K, Nakamura K, Takashima K, Seya T, Hazeki O, Kitazaki T, Iizawa Y: A novel cyclohexene derivative, TAK-242, selectively inhibits Toll-like receptor 4-mediated cytokine production through suppression of intracellular signaling. Mol Pharmacol 69:1288-1295, 2006.
7. Sha T, Sunamoto M, Kitazaki T, Sato J, Ii M, Iizawa Y: Therapeutic effects of TAK-242, a novel selective Toll-like receptor 4 signal transduction inhibitor, in mouse endotoxin shock model. Eur J Pharmacol 571:231-239, 2007.
8. Takashima K, Matsunaga N, Yoshimatsu M, Hazeki K, Kaisho T, Uekata M, Hazeki O, Akira S, Iizawa Y, Ii M: Analysis of binding site for the novel small-molecule TLR4 signal transduction inhibitor TAK-242 and its therapeutic effect on mouse sepsis model. Br J Pharmacol 157:1250-1262, 2009.
9. Hubbard WJ, Choudhry M, Schwacha MG, Kerby JD, Rue LW III, Bland KI, Chaudry IH: Cecal ligation and puncture. Shock 24(Suppl 1):52-57, 2005.
10. Rittirsch D, Huber-Lang MS, Flierl MA, Ward PA: Immunodesign of experimental sepsis by cecal ligation and puncture. Nat Protoc 4:31-36, 2009.
11. Brun-Buisson C, Doyon F, Carlet J, Dellamonica P, Gouin F, Lepoutre A, Mercier JC, Offenstadt G, Regnier B: Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. JAMA 274:968-974, 1995.
12. Hornef MW, Wick MJ, Rhen M, Normark S: Bacterial strategies for overcoming host innate and adaptive immune responses. Nat Immunol 3:1033-1040, 2002.
13. Parrish WR, Gallowitsch-Puerta M, Czura CJ, Tracey KJ: Experimental therapeutic strategies for severe sepsis: mediators and mechanisms. Ann N Y Acad Sci 1144:210-236, 2008.
14. Girbes AR, Beishuizen A, Strack van Schijndel RJ: Pharmacological treatment of sepsis. Fundam Clin Pharmacol 22:355-361, 2008.
15. Vianna RC, Gomes RN, Bozza FA, Amancio RT, Bozza PT, David CM, Castro-Faria-Neto HC: Antibiotic treatment in a murine model of sepsis: impact on cytokines and endotoxin release. Shock 21:115-120, 2004.
16. O'Sullivan AW, Wang JH, Redmond HP: NF-kappaB and p38 MAPK inhibition improve survival in endotoxin shock and in a cecal ligation and puncture model of sepsis in combination with antibiotic therapy. J Surg Res 152:46-53, 2009.
17. Lipman B, Neu HC: Imipenem: a new carbapenem antibiotic. Med Clin North Am 72:567-579, 1988.
18. Tsujimoto H, Ono S, Majima T, Kawarabayashi N, Takayama E, Kinoshita M, Seki S, Hiraide H, Moldawer LL, Mochizuki H: Neutrophil elastase, MIP-2, and TLR-4 expression during human and experimental sepsis. Shock 23:39-44, 2005.
19. Riedemann NC, Neff TA, Guo RF, Bernacki KD, Laudes IJ, Sarma JV, Lambris JD, Ward PA: Protective effects of IL-6 blockade in sepsis are linked to reduced C5a receptor expression. J Immunol 170:503-507, 2003.
20. Song GY, Chung CS, Chaudry IH, Ayala A: What is the role of interleukin 10 in polymicrobial sepsis: anti-inflammatory agent or immunosuppressant? Surgery 126:378-383, 1999.
21. Tsujimoto H, Ono S, Mochizuki H, Aosasa S, Majima T, Ueno C, Matsumoto A: Role of macrophage inflammatory protein 2 in acute lung injury in murine peritonitis. J Surg Res 103:61-67, 2002.
22. Koskinas J, Gomatos IP, Tiniakos DG, Memos N, Boutsikou M, Garatzioti A, Archimandritis A, Betrosian A: Liver histology in ICU patients dying from sepsis: a clinico-pathological study. World J Gastroenterol 14:1389-1393, 2008.
23. Schrier RW, Wang W: Acute renal failure and sepsis. N Engl J Med 351: 159-169, 2004.
24. Asaduzzaman M, Lavasani S, Rahman M, Zhang S, Braun OO, Jeppsson B, Thorlacius H: Platelets support pulmonary recruitment of neutrophils in abdominal sepsis. Crit Care Med 37:1389-1396, 2009.
25. Singer G, Urakami H, Specian RD, Stokes KY, Granger DN: Platelet recruitment in the murine hepatic microvasculature during experimental sepsis: role of neutrophils. Microcirculation 13:89-97, 2006.
26. Williams DL, Ha T, Li C, Kalbfleisch JH, Schweitzer J, Vogt W, Browder IW: Modulation of tissue Toll-like receptor 2 and 4 during the early phases of polymicrobial sepsis correlates with mortality. Crit Care Med 31:1808-1818, 2003.